Mutations in the nucleophosmin 1 (NPM1), fms-related tyrosine kinase 3 (FLT3) and CCAAT/enhancer binding protein alpha (CEBPA) genes, are clinically important prognostic markers of outcome and survival particularly for NK-AML [19, 20]. This evidence concerns the gene CEBPA and acute myeloid leukemia.